Smith & Nephew plc (NYSE:SNN) Shares Bought by Syon Capital LLC

Syon Capital LLC grew its holdings in Smith & Nephew plc (NYSE:SNN) by 89.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 20,250 shares of the medical equipment provider’s stock after purchasing an additional 9,534 shares during the quarter. Syon Capital LLC’s holdings in Smith & Nephew were worth $498,000 at the end of the most recent quarter.

A number of other hedge funds have also modified their holdings of the business. River Road Asset Management LLC grew its holdings in Smith & Nephew by 64.0% during the 4th quarter. River Road Asset Management LLC now owns 2,032,016 shares of the medical equipment provider’s stock valued at $49,947,000 after buying an additional 792,829 shares during the last quarter. Brandes Investment Partners LP lifted its position in shares of Smith & Nephew by 11.4% in the fourth quarter. Brandes Investment Partners LP now owns 1,363,039 shares of the medical equipment provider’s stock valued at $33,504,000 after acquiring an additional 138,994 shares in the last quarter. Clark Estates Inc. NY boosted its stake in shares of Smith & Nephew by 16.8% during the fourth quarter. Clark Estates Inc. NY now owns 800,000 shares of the medical equipment provider’s stock valued at $19,664,000 after acquiring an additional 115,000 shares during the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Smith & Nephew by 11.9% during the fourth quarter. Envestnet Asset Management Inc. now owns 535,350 shares of the medical equipment provider’s stock valued at $13,159,000 after acquiring an additional 57,014 shares during the last quarter. Finally, Causeway Capital Management LLC purchased a new stake in Smith & Nephew during the 4th quarter worth about $11,820,000. 25.64% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on SNN shares. StockNews.com raised shares of Smith & Nephew from a “buy” rating to a “strong-buy” rating in a research note on Wednesday, February 26th. Canaccord Genuity Group restated a “hold” rating and set a $27.00 target price on shares of Smith & Nephew in a research report on Monday, March 17th. Finally, UBS Group downgraded Smith & Nephew from a “buy” rating to a “neutral” rating in a report on Wednesday, March 12th. Four investment analysts have rated the stock with a hold rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus target price of $27.00.

Smith & Nephew Trading Up 1.8 %

NYSE SNN opened at $27.00 on Friday. The company has a market cap of $11.83 billion, a P/E ratio of 12.50, a P/E/G ratio of 1.26 and a beta of 0.71. Smith & Nephew plc has a 12 month low of $23.69 and a 12 month high of $31.72. The company has a debt-to-equity ratio of 0.63, a current ratio of 2.51 and a quick ratio of 1.11. The company has a 50-day moving average of $27.50 and a 200-day moving average of $26.37.

Smith & Nephew Increases Dividend

The business also recently declared a semi-annual dividend, which will be paid on Wednesday, May 28th. Shareholders of record on Friday, March 28th will be paid a dividend of $0.447 per share. The ex-dividend date is Friday, March 28th. This represents a yield of 2.5%. This is an increase from Smith & Nephew’s previous semi-annual dividend of $0.29. Smith & Nephew’s dividend payout ratio (DPR) is currently 41.20%.

Smith & Nephew Company Profile

Smith & Nephew plc engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics, Sports Medicine and ENT, and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies, and ENT.